Our Firm is investigating a number of cases where men are alleged to have suffered heart attacks, strokes and other serious cardiovascular problems due to low testosterone therapies. We are monitoring this issue very closely.
New York, New York (PRWEB) May 06, 2014
Pfizer, Inc., a defendant in testosterone treatment lawsuits (http://www.testosteronelawsuitcenter.com/) involving its Depo-Testosterone injection, is seeking to have those claims excluded from any multidistrict litigation involving cardiovascular injuries and low testosterone therapies, Bernstein Liebhard LLP reports. According to a Response in Opposition filed last week with the U.S. Judicial Panel on Multidistrict Litigation (JPML), the company contends that the proposed multidistrict litigation should be limited to claims involving testosterone drugs that are sold in gel form, such as AndroGel, Testim, Axiron and Foresta. Among other things, the response points out that Pfizer has only been named in 4 of the 85 testosterone lawsuits currently pending in federal courts, and asserts that there are important differences between those claims and cases involving the other medications. (In Re: AndroGel Product Liability Litigation, No. 2545, JPML)
“Our Firm is investigating a number of cases where men are alleged to have suffered heart attacks, strokes and other serious cardiovascular problems due to low testosterone therapies. We are monitoring this issue very closely,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm is currently offering free testosterone lawsuit reviews to anyone who may have suffered heart attacks, strokes, deep vein thrombosis, pulmonary embolism, or other serious heart problems allegedly due to the use of prescription testosterone therapies.
According to court documents, testosterone treatment lawsuits involving AndroGel, Testim, Depo-Testosterone and other medications used to treat hypogonadism (low testosterone) in men have been mounting in U.S. Courts since late January, when the Food & Drug Administration (FDA) announced it was investigating the heart risks potentially associated with low testosterone therapies. The FDA’s review was prompted by two studies that indicated the medications might raise the risk of heart attacks, strokes, and death in certain men, including older patients and those with pre-existing heart disease.
On March 28, 2014, plaintiffs in AndroGel lawsuits filed a brief with the JPML seeking to have those cases consolidated in a multidistrict litigation and transferred to the U.S. District Court, Northern District of Illinois, for coordinated pretrial proceedings. According to court documents, the manufacturers of AndroGel, Axiron and Foresta have since filed responses calling for the consolidation of all testosterone treatment lawsuits in that proposed multidistrict litigation, regardless of the drug used.
Court records also indicate that a second petition was filed with the JPML on April 11th which requests that a multidistrict litigation be established for all federally-filed testosterone lawsuits in the U.S. District Court, Eastern District of Pennsylvania. (In Re: Testosterone Products Liability Litigation, No. 42, JPML)
Men who allegedly experienced life-threatening cardiovascular events associated with the use of low testosterone therapies may be entitled to compensation for medical bills, lost wages, pain and suffering, and other damages. To learn more about filing a testosterone lawsuit, please visit Bernstein Liebhard LLP’s website. Free, no-obligation legal consultations can be obtained by calling 800-511-5092.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP represents the victims of defective drugs and medical devices on a contingency-fee basis, and our clients are never expected to pay attorneys fees unless their case results in a successful recovery on their behalf. New York State’s contingency fee cap rules generally limit those fees to 33 1/3% of the total recovery. As a result, the Firm’s fees can be significantly lower than those assessed by attorneys in other states, which depending on the law may amount to as much as 40% or more of a plaintiff’s recovery
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com